AnaptysBio (NASDAQ:ANAB) Shares Gap Up – Here’s What Happened

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $15.99, but opened at $16.46. AnaptysBio shares last traded at $16.52, with a volume of 185,473 shares trading hands.

Analyst Ratings Changes

ANAB has been the topic of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. UBS Group increased their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company cut their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. Wedbush reissued an “outperform” rating and issued a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Finally, HC Wainwright lowered AnaptysBio from a “buy” rating to a “neutral” rating and cut their price objective for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.18.

AnaptysBio Stock Down 4.1 %

The stock has a market cap of $466.78 million, a PE ratio of -2.52 and a beta of -0.11. The business has a 50 day moving average price of $24.91 and a 200 day moving average price of $29.41.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. On average, research analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in shares of AnaptysBio by 1.8% during the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after acquiring an additional 525 shares during the last quarter. Algert Global LLC raised its holdings in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 1,078 shares during the last quarter. nVerses Capital LLC raised its holdings in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of AnaptysBio during the third quarter valued at approximately $49,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.